# HER2 CISH pharmDx Kit

Source: https://onco.cc/drugs/her2-cish-pharmdx/  
OnCo record `her2-cish-pharmdx` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Dako's HER2 gene test read with an ordinary microscope, approved in 2011 to help decide on trastuzumab in breast cancer; the FDA records its approval as withdrawn in January 2018.

## Summary

The HER2 CISH pharmDx Kit from Dako Denmark A/S (Dako is now part of Agilent) was approved on 30 November 2011 (PMA P100024). The FDA approval statement describes dual-colour chromogenic in situ hybridisation, automated on Dako Autostainer instruments, that determines HER2 gene status in breast cancer tissue as an aid in assessing patients for whom trastuzumab is being considered. The FDA's PMA page for the kit gives a withdrawal date of 24 January 2018, and openFDA's copy of the same database gives the original approval the decision code APWD (withdrawal after approval). The FDA companion diagnostic list, last updated on 3 November 2026, still printed the kit.

## Fields

- Kind: Test
- Status: withdrawn
- Last checked: 2026-11-19
- Tags: test
- Brand: HER2 CISH pharmDx
- Modality: Chromogenic in situ hybridisation test (HER2 gene status, breast tumour tissue)
- Mechanism: Dual-colour chromogenic in situ hybridisation with labelled probes for the HER2 gene and the centromere of chromosome 17, giving red and blue signals on the same tissue section that are read under an ordinary bright-field microscope.
- Approvals: US 2011: HER2 gene status as an aid in selecting trastuzumab in breast cancer

## Notes

- The FDA PMA page for P100024 reads Withdrawal Date 01/24/2018 and the openFDA entry for the original approval reads decision_code APWD, both read 19 November 2026.

## Sources

- openFDA PMA record P100024 (original approval): https://api.fda.gov/device/pma.json?search=pma_number:P100024+AND+supplement_number:%22%22
- openFDA: PMA field definitions, including decision codes: https://open.fda.gov/fields/devicepma.yaml
- FDA PMA P100024: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100024
- FDA: List of FDA-Authorized Companion Diagnostic Devices: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools

## Connected records

- drugs: [HER2 FISH pharmDx Kit](https://onco.cc/drugs/her2-fish-pharmdx/), [HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)](https://onco.cc/drugs/her2-testing-assays/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [Agilent Technologies (Dako)](https://onco.cc/companies/agilent/)
- terms: [Companion diagnostic](https://onco.cc/terms/companion-diagnostic-term/), [HER2-positive (IHC 3+ or ISH-amplified)](https://onco.cc/terms/her2-positive/)

---
JSON: https://onco.cc/api/v1/entities/her2-cish-pharmdx.json